{"nctId":"NCT01628926","briefTitle":"A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients","startDateStruct":{"date":"2009-06"},"conditions":["Parkinson's Disease"],"count":420,"armGroups":[{"label":"SPM 962","type":"EXPERIMENTAL","interventionNames":["Drug: SPM 962"]},{"label":"Ropinirole","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ropinirole"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"SPM 962","otherNames":[]},{"name":"Ropinirole","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject diagnosed as having Parkinson's disease in accordance with \"Diagnostic Criteria established by the Research Committee of MHLW-specified Intractable Neurodegenerative Diseases (1995)\".\n* Subject is 30 and more and less than 80 years of age at the time of informed consent.\n* Hoehn \\& Yahr stage 2-4 (on time).\n* Total UPDRS Part 3 score is over 10 at screening test (on time).\n* Subject is on a stable dose of L-dopa with no change in daily dose or dosing regimen for at least 28 days prior to the initial treatment of SPM 962.\n* Subject has any of the following problematic symptoms; 1) Wearing off phenomenon (including frozen gait at off time and dystonia at off time) 2) On and off phenomenon 3) Delayed-on and/or No-on phenomenon 4) Dyskinesia 5) Not well controlled with L-dopa.\n\nExclusion Criteria:\n\n* Subject who has previously participated in a clinical trial of SPM962 and taken the investigational product (IP).\n* Subject has psychiatric symptoms, e.g. confusion, hallucination, delusion, excitation, delirium, abnormal behavior at screening test or baseline.\n* Subject whose SBP declines by at least 30 mmHg from supine to standing position based on the orthostatic hypotension assessment, or subject who develops orthostatic hypotension at baseline.\n* Subject has a history of epilepsy, convulsion and other.\n* Subject who has complications or a history of serious cardiac diseases or arrhythmia (eg, congestive heart failure of class 3 or 4 in the NYHA classification, second or third degree atrioventricular block, complete left bundle branch block, sick sinus syndrome, ventricular fibrillation, myocardial infarction within 12 months prior to the screening test, or a complication of angina pectoris).\n* Subjects has QTc-interval \\>450 msec twice at screening. Subject has a the average QTc-interval from two ECGs \\>450 msec in males and \\>470 msec in females at baseline.\n* Subject has congenital long QT syndrome.\n* Subject whose serum potassium level is \\< 3.5mEq/L at the screening test.\n* Subject has a total bilirubin \\>= 3.0 mg/dL or AST(GOT) or ALT(GPT) greater than 2.5 times of the upper limit of the reference range (or \\>= 100 IU/L) at screening test, or suffers complications of active phase of chronic hepatitis or liver cirrhosis.\n* Subject has BUN \\>= 30 mg/dL or serum creatinine \\>= 2.0 mg/dl at screening test.\n* Subject has a history of allergic reaction to topical agents such as transdermal patch.\n* Subject has a history of known intolerance/hypersensitivity to ropinirole and/or adverse drug reactions that prevent subject from receiving treatment.\n* Subject is pregnant or nursing or woman who plans pregnancy during the trial.\n* Subject is receiving therapy with prohibited drug specified in the study protocol.\n* Subject has a history of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant.\n* Subject has dementia, including DLB and PDD (MMSE score \\<= 24 at screening).\n* Subject who has a complication or history of malignant neoplastic disease, or received treatment for the disease within 12 months prior to the screening test.\n* Subject is unable to give consent.\n* Subject who is unable to properly record information in a diary.\n* Subject is participating in another trial of IPs or received other IPs within 12 weeks prior to commencement of study treatment.\n* Investigator judges that subject is inappropriate as a study subject with other reasons.","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","maximumAge":"79 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Unified Parkinson's Disease Rating Score (UPDRS) Part 3 Sum Score","description":"Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state) at 16 weeks after dosing.\n\nUPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.9","spread":"8.1"},{"groupId":"OG001","value":"-9.5","spread":"8.7"},{"groupId":"OG002","value":"-4.5","spread":"9.7"}]}]}]},{"type":"SECONDARY","title":"UPDRS Part 3 Sum Score","description":"Mean change (LOCF) from baseline in UPDRS Part 3 sum score (on state) at 8 and 10 weeks after dosing.\n\nUPDRS Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.7","spread":"7.2"},{"groupId":"OG001","value":"-8.4","spread":"8.1"},{"groupId":"OG002","value":"-5.5","spread":"8.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.9","spread":"7.1"},{"groupId":"OG001","value":"-8.8","spread":"8.3"},{"groupId":"OG002","value":"-5.3","spread":"9.0"}]}]}]},{"type":"SECONDARY","title":"UPDRS Part 2 Sum Score","description":"Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average scores of on state and off state) at 16 weeks after dosing.\n\nUPDRS 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"4.1"},{"groupId":"OG001","value":"-2.9","spread":"3.5"},{"groupId":"OG002","value":"-1.3","spread":"3.4"}]}]}]},{"type":"SECONDARY","title":"Off Time","description":"Mean change (LOCF) from baseline in off time at 16 weeks after dosing. Off-time is a state where L-Dopa becomes ineffective. Off-time was measured by patient diary in hours/day.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"2.9"},{"groupId":"OG001","value":"-2.0","spread":"3.0"},{"groupId":"OG002","value":"-0.4","spread":"2.7"}]}]}]},{"type":"SECONDARY","title":"Parkinson's Disease Sleep Scale-2 (PDSS-2)","description":"Mean change (LOCF) from baseline in PDSS-2 sum score at 16 weeks after dosing. PDSS-2 is a scale for assessing sleep disorders in Parkinson's disease. PDSS consists of 15 questions about sleep and nocturnal disturbances. The score of each question ranges from 0 (never) to 4 (very frequent). The sum of each question serves as the scale score. Thus a decrease in the scores means improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"6.8"},{"groupId":"OG001","value":"-3.4","spread":"7.6"},{"groupId":"OG002","value":"-1.8","spread":"7.0"}]}]}]},{"type":"SECONDARY","title":"On Time","description":"Mean change (LOCF) from baseline in on time at 16 weeks after dosing. On-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"2.7"},{"groupId":"OG001","value":"1.7","spread":"2.9"},{"groupId":"OG002","value":"0.2","spread":"2.6"}]}]}]},{"type":"SECONDARY","title":"On Time Without Dyskinesia Disturbing Daily Activities","description":"Mean change (LOCF) from baseline in on time without dyskinesia disturbing daily activities at 16 weeks after dosing.\n\nOn-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"2.9"},{"groupId":"OG001","value":"1.6","spread":"3.0"},{"groupId":"OG002","value":"0.3","spread":"2.6"}]}]}]},{"type":"SECONDARY","title":"On Time With Dyskinesia Disturbing Daily Activities","description":"Mean change (LOCF) from baseline in on time with dyskinesia disturbing daily activities at 16 weeks after dosing (rate against on time).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"11.0"},{"groupId":"OG001","value":"0.6","spread":"7.8"},{"groupId":"OG002","value":"-0.2","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Effective Rate in UPDRS Part 3 Sum Score","description":"Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 3 sum score (on state) at 16 weeks after dosing.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.5","spread":null},{"groupId":"OG001","value":"69.1","spread":null},{"groupId":"OG002","value":"56.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.5","spread":null},{"groupId":"OG001","value":"60.6","spread":null},{"groupId":"OG002","value":"39.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Effective Rate in UPDRS Part 2 Sum Score","description":"Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in UPDRS Part 2 sum score (average scores of on state and off state) at 16 weeks after dosing.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.2","spread":null},{"groupId":"OG001","value":"56.7","spread":null},{"groupId":"OG002","value":"47.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.9","spread":null},{"groupId":"OG001","value":"43.3","spread":null},{"groupId":"OG002","value":"28.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Effective Rate in Off Time","description":"Effective rate (percentage of subjects with 20% or 30% decrease) (LOCF) in off time at 16 weeks after dosing.\n\nOn-time is a state where L-Dopa is effective. On-time was measured by patient diary in hours/day.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.8","spread":null},{"groupId":"OG001","value":"65.5","spread":null},{"groupId":"OG002","value":"47.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.5","spread":null},{"groupId":"OG001","value":"61.9","spread":null},{"groupId":"OG002","value":"40.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression (CGI)","description":"Change (LOCF) from baseline in CGI score. CGI improvement is a clinician-reported scale for assessing how much the patient's illness has improved or worsened from baseline.\n\nThe scale scoring criteria are 1: very much improved, 2: much improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: much worse, 7: very much worse. A decrease in the scores means improvement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.3","spread":null},{"groupId":"OG001","value":"49.1","spread":null},{"groupId":"OG002","value":"30.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"8.5","spread":null},{"groupId":"OG002","value":"3.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"4.2","spread":null},{"groupId":"OG002","value":"4.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Dystonia (at an Early Hour)","description":"Change (LOCF) from baseline in occurrence of Dystonia (at an early hour).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":null},{"groupId":"OG001","value":"10.9","spread":null},{"groupId":"OG002","value":"7.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"4.2","spread":null},{"groupId":"OG002","value":"2.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"3.0","spread":null},{"groupId":"OG002","value":"3.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.6","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Dystonia (in the Daytime)","description":"Change (LOCF) from baseline in occurrence of Dystonia (in the daytime).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":null},{"groupId":"OG001","value":"7.9","spread":null},{"groupId":"OG002","value":"3.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"5.5","spread":null},{"groupId":"OG002","value":"2.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"2.4","spread":null},{"groupId":"OG002","value":"4.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"0.6","spread":null},{"groupId":"OG002","value":"1.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":168},"commonTop":["Application Site Reaction","Nasopharyngitis","Nausea","Dyskinesia","Hallucination Visual"]}}}